Unblocking Blockbusters: Using Boolean Text-Mining to Optimise Clinical Trial Design and Timeline for Novel Anticancer Drugs

Two problems now threaten the future of anticancer drug development: (i) the information explosion has made research into new target-specific drugs more duplication-prone, and hence less cost-efficient; and (ii) high-throughput genomic technologies have failed to deliver the anticipated early windfa...

Full description

Bibliographic Details
Main Author: Richard J. Epstein
Format: Article
Language:English
Published: SAGE Publishing 2009-01-01
Series:Cancer Informatics
Online Access:https://doi.org/10.4137/CIN.S2666
id doaj-bba15c9ff78f4998b5989e86dac7d38b
record_format Article
spelling doaj-bba15c9ff78f4998b5989e86dac7d38b2020-11-25T03:16:32ZengSAGE PublishingCancer Informatics1176-93512009-01-01710.4137/CIN.S2666Unblocking Blockbusters: Using Boolean Text-Mining to Optimise Clinical Trial Design and Timeline for Novel Anticancer DrugsRichard J. Epstein0Laboratory of Computational Oncology, Department of Medicine, The University of Hong Kong, Hong Kong.Two problems now threaten the future of anticancer drug development: (i) the information explosion has made research into new target-specific drugs more duplication-prone, and hence less cost-efficient; and (ii) high-throughput genomic technologies have failed to deliver the anticipated early windfall of novel first-in-class drugs. Here it is argued that the resulting crisis of blockbuster drug development may be remedied in part by innovative exploitation of informatic power. Using scenarios relating to oncology, it is shown that rapid data-mining of the scientific literature can refine therapeutic hypotheses and thus reduce empirical reliance on preclinical model development and early-phase clinical trials. Moreover, as personalised medicine evolves, this approach may inform biomarker-guided phase III trial strategies for noncytotoxic (antimetastatic) drugs that prolong patient survival without necessarily inducing tumor shrinkage. Though not replacing conventional gold standards, these findings suggest that this computational research approach could reduce costly ‘blue skies’ R&D investment and time to market for new biological drugs, thereby helping to reverse unsustainable drug price inflation.https://doi.org/10.4137/CIN.S2666
collection DOAJ
language English
format Article
sources DOAJ
author Richard J. Epstein
spellingShingle Richard J. Epstein
Unblocking Blockbusters: Using Boolean Text-Mining to Optimise Clinical Trial Design and Timeline for Novel Anticancer Drugs
Cancer Informatics
author_facet Richard J. Epstein
author_sort Richard J. Epstein
title Unblocking Blockbusters: Using Boolean Text-Mining to Optimise Clinical Trial Design and Timeline for Novel Anticancer Drugs
title_short Unblocking Blockbusters: Using Boolean Text-Mining to Optimise Clinical Trial Design and Timeline for Novel Anticancer Drugs
title_full Unblocking Blockbusters: Using Boolean Text-Mining to Optimise Clinical Trial Design and Timeline for Novel Anticancer Drugs
title_fullStr Unblocking Blockbusters: Using Boolean Text-Mining to Optimise Clinical Trial Design and Timeline for Novel Anticancer Drugs
title_full_unstemmed Unblocking Blockbusters: Using Boolean Text-Mining to Optimise Clinical Trial Design and Timeline for Novel Anticancer Drugs
title_sort unblocking blockbusters: using boolean text-mining to optimise clinical trial design and timeline for novel anticancer drugs
publisher SAGE Publishing
series Cancer Informatics
issn 1176-9351
publishDate 2009-01-01
description Two problems now threaten the future of anticancer drug development: (i) the information explosion has made research into new target-specific drugs more duplication-prone, and hence less cost-efficient; and (ii) high-throughput genomic technologies have failed to deliver the anticipated early windfall of novel first-in-class drugs. Here it is argued that the resulting crisis of blockbuster drug development may be remedied in part by innovative exploitation of informatic power. Using scenarios relating to oncology, it is shown that rapid data-mining of the scientific literature can refine therapeutic hypotheses and thus reduce empirical reliance on preclinical model development and early-phase clinical trials. Moreover, as personalised medicine evolves, this approach may inform biomarker-guided phase III trial strategies for noncytotoxic (antimetastatic) drugs that prolong patient survival without necessarily inducing tumor shrinkage. Though not replacing conventional gold standards, these findings suggest that this computational research approach could reduce costly ‘blue skies’ R&D investment and time to market for new biological drugs, thereby helping to reverse unsustainable drug price inflation.
url https://doi.org/10.4137/CIN.S2666
work_keys_str_mv AT richardjepstein unblockingblockbustersusingbooleantextminingtooptimiseclinicaltrialdesignandtimelinefornovelanticancerdrugs
_version_ 1724635620022681600